Endothelial nitric oxide synthase decreases beta-adrenergic responsiveness via inhibition of the L-type Ca2+ current

Honglan Wang1, Mark J Kohr, Debra G Wheeler

  • 1Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA.

Insights

Endothelial nitric oxide synthase (NOS3) signaling protects the heart from arrhythmias by reducing the response to beta-adrenergic stimulation. This pathway inhibits calcium currents, preventing dangerous heart rhythms, particularly relevant in heart failure.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Arrhythmogenesis

Background:

  • Endothelial nitric oxide synthase (NOS3) signaling is known to modulate cardiac function.
  • Its role in limiting beta-adrenergic (beta-AR) stimulation and preventing arrhythmias requires further mechanistic investigation.

Purpose of the Study:

  • To elucidate the mechanisms by which NOS3 signaling influences the cardiac response to beta-AR stimulation.
  • To determine the protective role of NOS3 against beta-AR-induced arrhythmias.

Main Methods:

  • Simultaneous measurements of action potential (AP), Ca2+ transients, and myocyte shortening in wild-type (WT) and NOS3 knockout (NOS3-/-) mouse myocytes.
  • Direct measurement of L-type Ca2+ current (ICa) using whole-cell patch-clamp.
  • Pharmacological inhibition of NOS3 using L-N5-(1-iminoethyl)-ornithine (l-NIO).

Main Results:

  • NOS3-/- myocytes exhibited increased early afterdepolarizations (EADs) and spontaneous activity upon beta-AR stimulation compared to WT.
  • Beta-AR stimulation caused a greater increase in ICa, Ca2+ transient amplitude, myocyte shortening, and AP duration in NOS3-/- myocytes.
  • NOS3 inhibition with l-NIO mimicked the effects of NOS3 knockout, exacerbating beta-AR-induced arrhythmias and electrophysiological changes.

Conclusions:

  • NOS3 signaling exerts a protective effect against beta-AR stimulation by inhibiting ICa, thereby preventing arrhythmias.
  • This inhibitory mechanism is crucial for maintaining cardiac stability and may be impaired in conditions like heart failure, contributing to increased arrhythmia risk.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...